The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Eradication therapy for peptic ulcer disease in Helicobacter pylori -positive people
Open accessAbstract
BACKGROUND: Peptic ulcer disease is the cause of dyspepsia in about 10% of people. Ninety-five percent of duodenal and 70% of gastric ulcers are associated with Helicobacter pylori. Eradication of H. pylori reduces the relapse rate of ulcers but the magnitude of this effect is uncertain. This is an update of Ford AC, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive patients. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003840. DOI: 10.1002/14651858.CD003840.pub4. OBJECTIVES: To assess the proportion of peptic ulcers healed and the proportion of participants who remained free from relapse with eradication therapy against placebo or other pharmacological therapies in H. pylori-positive people.To assess the proportion of participants that achieved complete relief of symptoms and improvement in quality of life scores.To compare the incidence of adverse effects/drop-outs (total number for each drug) associated with the different treatments.To assess the proportion of participants in whom successful eradication was achieved. SEARCH METHODS: In this update, we identified trials by searching the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE (1950 to March 2016) and Ovid EMBASE (1980 to March 2016). To identify further relevant trials, we handsearched reference lists from trials selected by electronic searching, and published abstracts from conference proceedings from the United European Gastroenterology Week (published in Gut) and Digestive Disease Week (published in Gastroenterology). The search was last updated in March 2016. We contacted members of Cochrane Upper GI and Pancreatic Diseases, and experts in the field and asked them to provide details of outstanding clinical trials and any relevant unpublished materials. SELECTION CRITERIA: We analysed randomised controlled trials of short- and long-term treatment of peptic ulcer disease in H. pylori-positive adults. Participants received at least one week of H. pylori eradication compared with ulcer healing drug, placebo or no treatment. Trials were included if they reported assessment from two weeks onwards. DATA COLLECTION AND ANALYSIS: We collected data on ulcer healing, recurrence, relief of symptoms and adverse effects. We calculated the risk ratio (RR) with 95% confidence intervals (CI) using both fixed-effect and random-effects models with Review Manager software (RevMan 5.3) based on intention-to-treat analysis as far as possible. MAIN RESULTS: A total of 55 trials were included for one or more outcomes for this review.In duodenal ulcer healing, eradication therapy was superior to ulcer healing drug (UHD) (34 trials, 3910 participants, RR of ulcer persisting = 0.66, 95% confidence interval (CI) 0.58 to 0.76; 381/2286 (adjusted proportion: 12.4%) in eradication therapy plus UHD versus 304/1624 (18.7%) in UHD; low quality evidence) and no treatment (two trials, 207 participants, RR 0.37, 95% CI 0.26 to 0.53; 30/125 (adjusted proportion: 21.7%) in eradication therapy versus 48/82 (58.5%) in no treatment; low quality evidence).In gastric ulcer healing, the differences were imprecise between eradication therapy and UHD (15 trials, 1974 participants, RR 1.23, 95% CI 0.90 to 1.68; 220/1192 (adjusted proportion: 16.0%) in eradication therapy plus UHD versus 102/782 (13.0%) in UHD; very low quality evidence). In preventing duodenal ulcer recurrence the differences were imprecise between maintenance therapy with H.pylori eradication therapy and maintenance therapy with UHD (four trials, 319 participants, RR of ulcer recurring 0.73; 95% CI 0.42 to 1.25; 19/159 (adjusted proportion: 11.9%) in eradication therapy versus 26/160 (16.3%) in UHD; very low quality evidence), but eradication therapy was superior to no treatment (27 trials 2509 participants, RR 0.20, 95% CI 0.15 to 0.26; 215/1501 (adjusted proportion: 12.9%) in eradication therapy versus 649/1008 (64.4%) in no treatment; very low quality evidence).In preventing gastric ulcer recurrence, eradication therapy was superior to no treatment (12 trials, 1476 participants, RR 0.31, 95% CI 0.22 to 0.45; 116/697 (adjusted proportion: 16.3%) in eradication therapy versus 356/679 (52.4%) in no treatment; very low quality evidence). None of the trials reported proportion of people with gastric ulcer not healed after initial therapy between H.pylori eradication therapy and no active treatment or the proportion of people with recurrent gastric ulcer or peptic ulcers during maintenance therapy between H.pylori eradication therapy and ulcer healing drug therapy. AUTHORS' CONCLUSIONS: Adding a one to two-week course of H. pylori eradication therapy is an effective treatment for people with H. pylori-positive duodenal ulcer when compared to ulcer healing drugs alone and no treatment. H. pylori eradication therapy is also effective in preventing recurrence of duodenal and gastric ulcer compared to no treatment. There is cu
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Malfertheiner, P., Mégraud, F., O'Morain, C., Hungin, A. P. S., Jones, R., Axon, A., Graham, D. Y., Tytgat, G., & The European Helicobacter Pylori Study Group (EHPSG) (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01169.x · Cited by 1,237
Cure of duodenal ulcer associated with eradication of Helicobacter pylori
Rauws, E. A. J., & Tytgat, G. N. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91301-p · Cited by 922
Graham, D. Y., Lew, G. M., Klein, P. D., Evans, D. G., Evans, D. J., Saeed, Z. A., & Malaty, H. M. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-9-705 · Cited by 909
Hentschel, E., Brandstatter, G., Dragosics, B., Hirschl, A. M., Nemec, H., Schutze, K., Taufer, M., & Wurzer, H. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302043280503 · Cited by 708
Summing up evidence: one answer is not always enough
Lau, J., Ioannidis, J. P., & Schmid, C. H. (1998) · The Lancet · doi:10.1016/s0140-6736(97)08468-7 · Cited by 655
Lind, T., van Zanten, S. V., Unge, P., Spiller, R., Bayerdörffer, E., O'Morain, C., Bardhan, K. D., Bradette, M., Chiba, N., Wrangstadh, M., et al. (1996) · Helicobacter · doi:10.1111/j.1523-5378.1996.tb00027.x · Cited by 573
Guidelines for the management of Helicobacter pylori infection
Howden, C. W., & Hunt, R. H. (1998) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.00684.x · Cited by 411
Cited by
Oxidative Stress: An Essential Factor in the Pathogenesis of Gastrointestinal Mucosal Diseases
Bhattacharyya, A., Chattopadhyay, R., Mitra, S., & Crowe, S. E. (2014) · Physiological Reviews · doi:10.1152/physrev.00040.2012 · Cited by 2,484
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
Malfertheiner, P., Megraud, F., O'Morain, C. A., Atherton, J., Axon, A. T. R., Bazzoli, F., Gensini, G. F., Gisbert, J. P., Graham, D. Y., Rokkas, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302084 · Cited by 2,266
Malfertheiner, P., Chan, F. K., & McColl, K. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60938-7 · Cited by 1,488
ACG and CAG Clinical Guideline: Management of Dyspepsia
Moayyedi, P. M., Lacy, B. E., Andrews, C. N., Enns, R. A., Howden, C. W., & Vakil, N. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.154 · Cited by 689
Self-citationHearnshaw, S. A., Logan, R. F. A., Lowe, D., Travis, S. P. L., Murphy, M. F., & Palmer, K. R. (2011) · Gut · doi:10.1136/gut.2010.228437 · Cited by 673
Metadata
- Authors
- Ford, A. C., Gurusamy, K. S., Delaney, B., Forman, D., & Moayyedi, P.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-04-19
- Volume
- 2016
- Issue
- 4
- Pages
- CD003840-CD003840
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1938376174
- Cited by
- 287
- References
- 51
- FWCI
- 20.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eradication therapy for peptic ulcer disease in Helicobacter pylori -positive people. https://app.cochat.ai/papers/10.1002/14651858.cd003840.pub5
- The paper
- Ford, A. C., Gurusamy, K. S., Delaney, B., Forman, D., & Moayyedi, P. (2016). Eradication therapy for peptic ulcer disease in Helicobacter pylori -positive people. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd003840.pub5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.